Viriom successfully completes clinical safety trial with novel NNRTI, advances to efficacy studies in HIV-infected patients, and to development of HIV microbicide formulation
The Russian Corporation of Nanotechnologies (known as Rusnano) in Moscow, along with a yet-to-be announced co-investor, plans to fund the development of up to 15 potential drug molecules that have unique mechanisms of action, taking them from the preclinical development stage through to Phase 2 clinical trials. "We expect that of the 15 compounds, a few will support the investment," says Andrey Ivaschenko, chairman of ChemRar, the Moscow-based pharmaceutical and biotechnology services company that will provide the first five target molecules. Although the investment is not a huge sum, he notes, a compound can be developed to the Phase 2 clinical stage in Russia for $5-10 million.
Rabochaya St. 2-a, bldg. 1
Khimki, Moscow
141400, Russia
Phone: +7 (495) 995-4944
Fax: +7 (495) 626-9780
www.viriom.com
Partners
Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.
In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.
For more information: www.roche.com
CHEMRAR Hi-Tech Center
ChemRar is a unique pharma and biotechnology conglomerate built in Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide. The mission of the company is to develop and commercialise existing drugs on the basis of novel “post-genomic” technologies used for treatment of cancer, infectious, cardiovascular and central nervous system (CNS) diseases as well metabolic disorders. ChemRar performs a full cycle of pre-clinical and clinical research of new molecules including screening and identification of the essential biological targets for new molecules, synthesis and research of new molecules as well as full cycle of production.
For more information: www.chemrar.ru
Chemical Diversity Research Institute (CDRI)
(CDRI) - is a contract research organization focused on pre-clinical and clinical R&D from target identification to clinical candidate nomination and Proof of Concept in human. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource™ platforms. Since 1990 we continue extending quality R&D services in CNS, oncology, inflammation, CV and metabolic disease area to the pharma and biotech partners.
CDRI’s collaboration network encompasses hundreds of scientific institutions and individual research groups in Russia, CIS countries and rest of the world. The Institute has established broad cooperation with the Moscow State University, Moscow Institute of Physics and Technology, D. Mendeleev University of Chemical Technology of Russia and other in science and education fields. CDRI offers internships, graduate and postdoctoral positions to young scientists, attracting returnees with US and European industrial experience thus enhancing the core basic and application sciences and pharmaceutical industrial expertise in Russian Federation.
For more information: www.iihr.ru
DRUGS TECHNOLOGY, Ltd.
DRUGS TECHNOLOGY, Ltd. is
the pharmaceutical development company.
DRUGS TECHNOLOGY is created on the basis of Chemical Diversity Research Institute, Russia. CDRI is the big
scientific and technical complex which is engaged in the combinatory synthesis
and high-speed screening of biologically active molecules.
DRUGS TECHNOLOGY is the service company which gives vast spectrum of
qualitative services for pharmaceutical companies essentially by development
modern effective hi-tech and highly profitable generics.
For more information: www.drugsformulation.ru
ChemDiv, Inc.
ChemDiv is a global discovery and development organization headquartered in San Diego, CA, USA with subsidiaries in Russia, business and logistics operations around the world.
ChemDiv is a provider of integrated discovery and development solutions based on a strong chemistry platform. Integrated Discovery outSource™ solutions offered by ChemDiv cover the complete range of disciplines needed to bring a project in CNS, oncology, inflammation, metabolic and infectious disease area from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate ( Phase I and II).
For more information: www.chemdiv.com
« Back